Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Current Assets (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Current Assets for 15 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 7.92% to $23.0 million in Q4 2025 year-over-year; TTM through Oct 2025 was $23.0 million, a 7.92% increase, with the full-year FY2025 number at $22.4 million, down 55.64% from a year prior.
  • Current Assets was $23.0 million for Q4 2025 at PharmaCyte Biotech, up from $19.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $87.2 million in Q4 2021 to a low of $1.5 million in Q3 2021.
  • A 5-year average of $48.1 million and a median of $56.0 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 5353.31% in 2022, then crashed 72.42% in 2025.
  • PharmaCyte Biotech's Current Assets stood at $87.2 million in 2021, then fell by 11.43% to $77.2 million in 2022, then fell by 4.49% to $73.7 million in 2023, then crashed by 71.07% to $21.3 million in 2024, then increased by 7.92% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Current Assets are $23.0 million (Q4 2025), $19.1 million (Q3 2025), and $22.4 million (Q2 2025).